CTLA4 and neoplasm: Interestingly, a blockade of CTLA4 in preclinical murine cancer models restores effector T-cells and decreases Tregs in melanoma [49,50] and colorectal cancer [51], demonstrating the important role of this molecule in tumor immune evasion.